1 Monneret, C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr 69, 286-295 (2011). https://doi.org/10.1016/j.pharma.2011.10.001
2 Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482-491 (2010). https://doi.org/10.1038/onc.2009.356
3 Gillespie, K. P., Pirnie, R., Mesaros, C. & Blair, I. A. Cisplatin Dependent Secretion of Immunomodulatory High Mobility Group Box 1 (HMGB1) Protein from Lung Cancer Cells. Biomolecules 13, 1335 (2023). https://doi.org/10.3390/biom13091335
4 Fucikova, J. et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11, 1013 (2020). https://doi.org/10.1038/s41419-020-03221-2
5 Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202, 1691-1701 (2005). https://doi.org/10.1084/jem.20050915
6 Weng, L., Guo, L., Vachani, A., Mesaros, C. & Blair, I. A. Quantification of Serum High Mobility Group Box 1 by Liquid Chromatography/High-Resolution Mass Spectrometry: Implications for Its Role in Immunity, Inflammation, and Cancer. Anal Chem 90, 7552-7560 (2018). https://doi.org/10.1021/acs.analchem.8b01175
7 Starkova, T., Polyanichko, A., Tomilin, A. N. & Chikhirzhina, E. Structure and Functions of HMGB2 Protein. Int J Mol Sci 24 (2023). https://doi.org/10.3390/ijms24098334
8 Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342 (2005). https://doi.org/10.1038/nri1594
9 Niu, L. et al. Biological functions and theranostic potential of HMGB family members in human cancers. Ther Adv Med Oncol 12, 1758835920970850 (2020). https://doi.org/10.1177/1758835920970850
10 Ikram, F. Z., Arulsamy, A., Retinasamy, T. & Shaikh, M. F. The Role of High Mobility Group Box 1 (HMGB1) in Neurodegeneration: A Systematic Review. Curr Neuropharmacol 20, 2221-2245 (2022). https://doi.org/10.2174/1570159X20666220114153308
11 Paudel, Y. N. et al. Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting. Cells 9 (2020). https://doi.org/10.3390/cells9020383
12 Wang, M. et al. The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases. Antioxid Redox Signal 31, 954-993 (2019). https://doi.org/10.1089/ars.2019.7818
13 Wu, T. et al. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget 7, 50417-50427 (2016). https://doi.org/10.18632/oncotarget.10413
14 Palanissami, G. & Paul, S. F. D. RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review. Horm Cancer 9, 295-325 (2018). https://doi.org/10.1007/s12672-018-0342-9
15 Kang, R. & Tang, D. The Dual Role of HMGB1 in Pancreatic Cancer. J Pancreatol 1, 19-24 (2018).
16 Plemmenos, G., Tzimogianni, V., Fili, C. & Piperi, C. Contributing Role of High Mobility Group Box 1 Signaling in Oral Cancer Development and Therapy. Life (Basel) 13 (2023). https://doi.org/10.3390/life13071577
17 Barreiro-Alonso, A. et al. High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev 2016, 5845061 (2016). https://doi.org/10.1155/2016/5845061
18 Wu, X. J., Chen, Y. Y., Gong, C. C. & Pei, D. S. The role of high-mobility group protein box 1 in lung cancer. J Cell Biochem 119, 6354-6365 (2018). https://doi.org/10.1002/jcb.26837
19 Pusterla, T., de Marchis, F., Palumbo, R. & Bianchi, M. E. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 42, 308-310 (2009). https://doi.org/10.1080/08916930902831845
20 Neubert, E. N. et al. HMGB2 regulates the differentiation and stemness of exhausted CD8(+) T cells during chronic viral infection and cancer. Nat Commun 14, 5631 (2023). https://doi.org/10.1038/s41467-023-41352-0
21 Ronfani, L. et al. Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 128, 1265-1273 (2001). https://doi.org/10.1242/dev.128.8.1265
22 Abraham, A. B. et al. Members of the high mobility group B protein family are dynamically expressed in embryonic neural stem cells. Proteome Sci 11, 18 (2013). https://doi.org/10.1186/1477-5956-11-18
23 Benavides Damm, T. & Egli, M. Calcium's role in mechanotransduction during muscle development. Cell Physiol Biochem 33, 249-272 (2014). https://doi.org/10.1159/000356667
24 Davies, J. E., Apta, B. H. R. & Harper, M. T. Cross-reactivity of anti-HMGB1 antibodies for HMGB2. J Immunol Methods 456, 72-76 (2018). https://doi.org/10.1016/j.jim.2018.02.006
25 Pirnie, R., Gillespie, K. P., Weng, L., Mesaros, C. & Blair, I. A. Characterization and Quantification of Oxidized High Mobility Group Box 1 Proteoforms Secreted from Hepatocytes by Toxic Levels of Acetaminophen. Chem Res Toxicol 35, 1893-1902 (2022). https://doi.org/10.1021/acs.chemrestox.2c00161
26 Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat Immunol 23, 487-500 (2022). https://doi.org/10.1038/s41590-022-01132-2
27 Sprooten, J. et al. Trial watch: chemotherapy-induced immunogenic cell death in oncology. Oncoimmunology 12, 2219591 (2023). https://doi.org/10.1080/2162402X.2023.2219591
28 Robinson, C. & Bolhuis, A. Protein targeting by the twin-arginine translocation pathway. Nat Rev Mol Cell Biol 2, 350-356 (2001). https://doi.org/10.1038/35073038
29 Wang, Y., Fan, S., Zhong, W., Zhou, X. & Li, S. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Int J Mol Sci 18 (2017). https://doi.org/10.3390/ijms18091860
30 Liang, W. J., Yang, H. W., Liu, H. N., Qian, W. & Chen, X. L. HMGB1 upregulates NF-kB by inhibiting IKB-alpha and associates with diabetic retinopathy. Life Sci 241, 117146 (2020). https://doi.org/10.1016/j.lfs.2019.117146
31 Wu, H. et al. HMGB2 Deficiency Mitigates Abdominal Aortic Aneurysm by Suppressing Ang-II-Caused Ferroptosis and Inflammation via NF-kappabeta Pathway. Mediators Inflamm 2023, 2157355 (2023). https://doi.org/10.1155/2023/2157355
32 Casper, E. The crosstalk between Nrf2 and NF-kappaB pathways in coronary artery disease: Can it be regulated by SIRT6? Life Sci 330, 122007 (2023). https://doi.org/10.1016/j.lfs.2023.122007
33 Xiang, Y., Song, X. & Long, D. Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases. Arch Toxicol 98, 579-615 (2024). https://doi.org/10.1007/s00204-023-03660-8
34 Lin, X., Ping, J., Wen, Y. & Wu, Y. The Mechanism of Ferroptosis and Applications in Tumor Treatment. Front Pharmacol 11, 1061 (2020). https://doi.org/10.3389/fphar.2020.01061
35 Wang, M. et al. Protective effect of FXN overexpression on ferroptosis in L-Glu-induced SH-SY5Y cells. Acta Histochem 126, 152135 (2024). https://doi.org/10.1016/j.acthis.2024.152135
36 Tesniere, A. et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15, 3-12 (2008). https://doi.org/10.1038/sj.cdd.4402269
37 Park, J. S. et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290, C917-924 (2006). https://doi.org/10.1152/ajpcell.00401.2005
38 Yu, M. et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006). https://doi.org/10.1097/01.shk.0000225404.51320.82
39 Tian, J. et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8, 487-496 (2007). https://doi.org/10.1038/ni1457
40 Hori, O. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270, 25752-25761 (1995). https://doi.org/10.1074/jbc.270.43.25752
41 Watanabe, H. & Son, M. The Immune Tolerance Role of the HMGB1-RAGE Axis. Cells 10 (2021). https://doi.org/10.3390/cells10030564
42 Ren, W., Zhao, L., Sun, Y., Wang, X. & Shi, X. HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases. Mol Med 29, 117 (2023). https://doi.org/10.1186/s10020-023-00717-3
43 Tang, D., Kang, R., Zeh, H. J. & Lotze, M. T. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol 23, 824-841 (2023). https://doi.org/10.1038/s41577-023-00894-6
44 Pusterla, T., de Marchis, F., Palumbo, R. & Bianchi, M. E. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 42, 308-310 (2009). https://doi.org/10.1080/08916930902831845
45 Liu, Z. H. et al. Association of serum HMGB2 level with MACE at 1 mo of myocardial infarction: Aggravation of myocardial ischemic injury in rats by HMGB2 via ROS. Am J Physiol Heart Circ Physiol 312, H422-H436 (2017). https://doi.org/10.1152/ajpheart.00249.2016
46 Zitvogel, L. et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16, 3100-3104 (2010). https://doi.org/10.1158/1078-0432.CCR-09-2891
47 Martins, I. et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30, 1147-1158 (2011). https://doi.org/10.1038/onc.2010.500
48 Sen, S., Karoscik, K., Maier, E. & Arambula, J. F. Immunogenic cell death-inducing metal complexes: From the benchtop to the clinic. Curr Opin Chem Biol 73, 102277 (2023). https://doi.org/10.1016/j.cbpa.2023.102277
49 Matsusaka, K. et al. Distinct roles in phagocytosis of the early and late increases of cell surface calreticulin induced by oxaliplatin. Biochem Biophys Rep 29, 101222 (2022). https://doi.org/10.1016/j.bbrep.2022.101222
50 O’Dowd, D., Sutcliffe, D. F. & Griffith, D. M. Oxaliplatin and its derivatives – An overview. Coord Chem Rev 497, 215-439 (2023).
51 Zhai, J. et al. Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Front Pharmacol 14, 1152934 (2023). https://doi.org/10.3389/fphar.2023.1152934
52 Chen, R., Kang, R. & Tang, D. The mechanism of HMGB1 secretion and release. Exp Mol Med 54, 91-102 (2022). https://doi.org/10.1038/s12276-022-00736-w
53 Bian, B. et al. Cathepsin B promotes colorectal tumorigenesis, cell invasion, and metastasis. Mol Carcinog 55, 671-687 (2016). https://doi.org/10.1002/mc.22312
54 Siwach, K. et al. 1,2,3-Triazole-based esters and carboxylic acids as nonclassical carbonic anhydrase inhibitors capable of cathepsin B inhibition. Arch Pharm (Weinheim), e2300372 (2023). https://doi.org/10.1002/ardp.202300372
55 William-Faltaos, S., Rouillard, D., Lechat, P. & Bastian, G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res 26, 2093-2099 (2006).
56 Gourdier, I., Crabbe, L., Andreau, K., Pau, B. & Kroemer, G. Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA. Oncogene 23, 7449-7457 (2004). https://doi.org/10.1038/sj.onc.1208047
57 Yang, C., Zhang, Y., Lin, S., Liu, Y. & Li, W. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging (Albany NY) 13, 13515-13534 (2021). https://doi.org/10.18632/aging.202774
58 Al-Otaibi, W. A. & AlMotwaa, S. M. Oxaliplatin-loaded nanoemulsion containing Teucrium polium L. essential oil induces apoptosis in Colon cancer cell lines through ROS-mediated pathway. Drug Deliv 29, 2190-2205 (2022). https://doi.org/10.1080/10717544.2022.2096711
59 He, Y. et al. Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression. Redox Biol 65, 102822 (2023). https://doi.org/10.1016/j.redox.2023.102822
60 Huang, Y. et al. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis. Sci Rep 13, 14359 (2023). https://doi.org/10.1038/s41598-023-41490-x
61 Liu, X. et al. FOXA2 Suppression by TRIM36 Exerts Anti-Tumor Role in Colorectal Cancer Via Inducing NRF2/GPX4-Regulated Ferroptosis. Adv Sci (Weinh) 10, e2304521 (2023). https://doi.org/10.1002/advs.202304521
62 Hadian, K. & Stockwell, B. R. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov 22, 723-742 (2023). https://doi.org/10.1038/s41573-023-00749-8
63 Wardyn, J. D., Ponsford, A. H. & Sanderson, C. M. Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways. Biochem Soc Trans 43, 621-626 (2015). https://doi.org/10.1042/BST20150014
64 Hu, P. et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11. Eur J Pharmacol 928, 175093 (2022). https://doi.org/10.1016/j.ejphar.2022.175093
65 Cotticelli, M. G. et al. Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia. J Pharmacol Exp Ther 369, 47-54 (2019). https://doi.org/10.1124/jpet.118.252759
66 Koutsodendris, N. et al. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell Rep 42, 113252 (2023). https://doi.org/10.1016/j.celrep.2023.113252
67 Liu, P. et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology 11, 2093518 (2022). https://doi.org/10.1080/2162402X.2022.2093518
68 Bezu, L., Kepp, O. & Kroemer, G. Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors. Oncoimmunology 12, 2272352 (2023). https://doi.org/10.1080/2162402X.2023.2272352
69 Schroeder, A. B. et al. The ImageJ ecosystem: Open-source software for image visualization, processing, and analysis. Protein Sci 30, 234-249 (2021). https://doi.org/10.1002/pro.3993
70 MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (2010). https://doi.org/10.1093/bioinformatics/btq054